• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对仅接受放射治疗作为初始治疗后复发的临床I期或II期霍奇金病患者的生存分析。

Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone.

作者信息

Horwich A, Specht L, Ashley S

机构信息

Academic Unit of Radiotherapy and Oncology, Royal Marsden NHS Trust, Sutton, Surrey, U.K.

出版信息

Eur J Cancer. 1997 May;33(6):848-53. doi: 10.1016/s0959-8049(96)00518-7.

DOI:10.1016/s0959-8049(96)00518-7
PMID:9291804
Abstract

To aid treatment choice in early stage of Hodgkin's disease, we analysed patients registered in the IDHD Database with clinical stages I or II Hodgkin's disease who were not staged with laparotomy and whose initial treatment was with radiotherapy alone. The factors analysed for outcome after first relapse included initial stage, age, sex, histology, number of involved areas, mediastinal involvement, E-lesions, B-symptoms, erythrocyte sedimentation rate, alkaline phosphatase, serum albumin and haemoglobin. As well as presentation variables, we analysed the disease-free interval after initial radiotherapy and the extent of disease at relapse. A total of 1364 patients with clinical stage I or II Hodgkin's disease were treated with initial radiotherapy, of whom 473 relapsed. The probability of survival 10 years after relapse was 63%. For cause-specific survival (CSS), both multivariate and univariate analysis identified the importance of age at presentation and histological subtypes. When all causes of death were considered, the multivariate analysis identified age as the only significant factor. The length of initial disease-free interval had no influence on prognosis after relapse, but the 169 patients with nodal relapse had a higher cause-specific survival than those with an extranodal component of relapse (74% versus 51% at 10 years, P < 0.005). Thus, the important factors for outcome after initial treatment with radiotherapy are those factors predicting the risk of relapse after initial treatment together with those predicting outcome after relapse, namely age, histologic subtype and extent of disease at relapse.

摘要

为了辅助霍奇金淋巴瘤早期治疗方案的选择,我们分析了国际霍奇金淋巴瘤数据库(IDHD)中登记的临床I期或II期霍奇金淋巴瘤患者,这些患者未接受剖腹探查分期,且初始治疗仅为放疗。分析首次复发后预后的因素包括初始分期、年龄、性别、组织学类型、受累区域数量、纵隔受累情况、E病变、B症状、红细胞沉降率、碱性磷酸酶、血清白蛋白和血红蛋白。除了临床表现变量外,我们还分析了初始放疗后的无病间期以及复发时的疾病范围。共有1364例临床I期或II期霍奇金淋巴瘤患者接受了初始放疗,其中473例复发。复发后10年的生存率为63%。对于特定病因生存率(CSS),多因素和单因素分析均确定了发病年龄和组织学亚型的重要性。当考虑所有死亡原因时,多因素分析确定年龄是唯一的显著因素。初始无病间期的长短对复发后的预后没有影响,但169例淋巴结复发患者的特定病因生存率高于有结外复发成分的患者(10年时分别为74%和51%,P<0.005)。因此,初始放疗后预后的重要因素是那些预测初始治疗后复发风险的因素以及那些预测复发后预后的因素,即年龄、组织学亚型和复发时的疾病范围。

相似文献

1
Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone.对仅接受放射治疗作为初始治疗后复发的临床I期或II期霍奇金病患者的生存分析。
Eur J Cancer. 1997 May;33(6):848-53. doi: 10.1016/s0959-8049(96)00518-7.
2
Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease.对采用剖腹探查分期且初始仅接受放疗的临床I期或II期霍奇金病患者复发后的挽救性治疗。来自国际霍奇金病数据库的一份报告。
Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):805-11. doi: 10.1016/0360-3016(94)90353-0.
3
[A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].[某放疗诊所霍奇金病治疗结果的回顾性分析]
Strahlenther Onkol. 1994 Sep;170(9):516-23.
4
Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression.Ann Arbor I期霍奇金淋巴瘤的长期治疗结果:生存及无进展生存的预后因素
Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):593-9. doi: 10.1016/s0360-3016(97)00036-9.
5
Radiotherapy results in laparotomy-staged Hodgkin's disease.放射治疗导致剖腹分期的霍奇金淋巴瘤。
Clin Radiol. 1988 Jul;39(4):428-31. doi: 10.1016/s0009-9260(88)80294-0.
6
Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria.淋巴细胞为主型霍奇金淋巴瘤:基于当前组织病理学标准的长期结果
Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):329-34. doi: 10.1016/s0360-3016(98)00389-7.
7
Radiation therapy in clinical stage I and II Hodgkin's disease. The Princess Margaret Hospital Lymphoma Group.临床I期和II期霍奇金病的放射治疗。玛格丽特公主医院淋巴瘤研究组。
Eur J Cancer. 1992;28A(11):1841-6. doi: 10.1016/0959-8049(92)90017-v.
8
Long-term follow-up of patients treated with primary radiotherapy for supradiaphragmatic Hodgkin's disease at St. Jude Children's Research Hospital.圣犹大儿童研究医院对接受原发性放疗的膈上型霍奇金病患者的长期随访。
Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):867-77. doi: 10.1016/s0360-3016(99)00052-8.
9
Pelvic relapse following subtotal lymphoid irradiation in early stage Hodgkin's disease--an analysis of risk, management, and outcome.早期霍奇金淋巴瘤全淋巴结照射后盆腔复发——风险、管理及结局分析
Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1239-44. doi: 10.1016/0360-3016(94)00607-m.
10
Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors.膈下I期和II期霍奇金淋巴瘤:长期随访及预后因素
Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1047-56. doi: 10.1016/s0360-3016(98)00151-5.

引用本文的文献

1
Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion.结节性淋巴细胞为主型霍奇金淋巴瘤:文献复习与病例讨论。
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221111767. doi: 10.1177/23247096221111767.
2
Overview and outcome of Hodgkin's Lymphoma: Experience of a single developing country's oncology centre.霍奇金淋巴瘤概述及转归:单一发展中国家肿瘤中心的经验。
PLoS One. 2018 Apr 12;13(4):e0195629. doi: 10.1371/journal.pone.0195629. eCollection 2018.
3
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.
美国放射学会适宜性标准® 复发性霍奇金淋巴瘤
Oncology (Williston Park). 2016 Dec 15;30(12):1099-103, 1106-8.
4
The GHSG Approach to Treating Hodgkin's Lymphoma.德国霍奇金淋巴瘤研究组(GHSG)治疗霍奇金淋巴瘤的方法。
Curr Hematol Malig Rep. 2015 Sep;10(3):256-65. doi: 10.1007/s11899-015-0262-5.
5
Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group.针对中危霍奇金淋巴瘤的基于反应的治疗的3期研究(AHOD0031)中的复发模式:来自儿童肿瘤学组的报告
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):60-6. doi: 10.1016/j.ijrobp.2014.10.042. Epub 2014 Dec 24.
6
State of the art in the treatment of Hodgkin lymphoma.霍奇金淋巴瘤治疗的最新进展。
Nat Rev Clin Oncol. 2012 Jun 12;9(8):450-9. doi: 10.1038/nrclinonc.2012.91.
7
First-line treatment of Hodgkin's lymphoma.霍奇金淋巴瘤的一线治疗。
Curr Hematol Malig Rep. 2006 Mar;1(1):51-9. doi: 10.1007/s11899-006-0018-3.
8
[Modern pharmacotherapy of Hodgkin disease].[霍奇金病的现代药物治疗]
Internist (Berl). 2004 Jan;45(1):93-101. doi: 10.1007/s00108-003-1094-2.
9
Current treatment strategies in early stage Hodgkin's disease.
Curr Treat Options Oncol. 2003 Aug;4(4):297-305. doi: 10.1007/s11864-003-0005-z.
10
Early-stage Hodgkin's disease.早期霍奇金淋巴瘤
Curr Oncol Rep. 2001 May;3(3):279-84. doi: 10.1007/s11912-001-0062-z.